Podcast
Questions and Answers
Which of the following patients would qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
Which of the following patients would qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
- A patient with type 2 diabetes and an HbA1c of 52 mmol/mol, despite regular use of metformin for 3 months (correct)
- A patient with type 2 diabetes and an HbA1c of 55 mmol/mol, despite regular use of metformin for 6 months
- A patient with type 2 diabetes and an HbA1c of 48 mmol/mol, despite regular use of metformin for 4 months
- A patient with type 2 diabetes and an HbA1c of 50 mmol/mol, despite regular use of metformin for 2 months
Which of the following is NOT a criterion for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
Which of the following is NOT a criterion for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
- Diabetic renal disease
- Known CV disease
- Māori or Pacific ethnicity
- Five-year CV risk < 15% (correct)
Why are ethnicity and age-group clauses included in the Special Authority criteria for funded SGLT2i and GLP1RA therapy?
Why are ethnicity and age-group clauses included in the Special Authority criteria for funded SGLT2i and GLP1RA therapy?
- Because these agents are more effective in these groups
- To reduce barriers in high-risk populations (correct)
- Because of financial constraints
- To exclude certain patient populations
Which of the following patients should be offered the opportunity to self-fund empagliflozin and/or liraglutide or dulaglutide?
Which of the following patients should be offered the opportunity to self-fund empagliflozin and/or liraglutide or dulaglutide?
What is the reason for not allowing patients to be on funded empagliflozin and dulaglutide or liraglutide at the same time?
What is the reason for not allowing patients to be on funded empagliflozin and dulaglutide or liraglutide at the same time?
What additional benefits can be expected from dual SGLT2i/GLP1RA therapy?
What additional benefits can be expected from dual SGLT2i/GLP1RA therapy?
Which of the following patients would NOT qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
Which of the following patients would NOT qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
What is the purpose of the Special Authority criteria?
What is the purpose of the Special Authority criteria?
